Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and a key regulator of angiogenesis in a variety of physiologic and pathologic processes (1 ) . The human gene for VEGF resides on chromosome 6p21.3 and is organized into 8 exons (2, 3 ) . Alternative exon splicing of the VEGF gene produces various splice variants (subscripts denote the number of amino acids after signal sequence cleavage): VEGF 206 , VEGF 189 , VEGF 183 , VEGF 165 , VEGF 148 , VEGF 145 , and VEGF 121 (4 -8 ) . Exons 1-5 and 8 are preserved in all variants, whereas the presence or absence of exons 6a, 6b, and 7 distinguish variants. VEGF 121 lacks these exons (4 ), VEGF 165 contains the exon 7-encoded sequence (4 ) , and VEGF 148 has the same amino acid sequence as VEGF 165 apart from a 35-bp-long deletion at the end of exon 7 (5 ) . VEGF 189 contains exons 6a and 7 (4 ), whereas in VEGF 183 the final 18 bp of exon 6a are missing (6 ) . VEGF 145 contains exon 6a but lacks exon 7 (7 ). VEGF 206 is the full-length form containing, in addition to exons 6a and 7, a 51-bp part from intron 3, exon 6b, neighboring exon 6a (8 ) .
VEGF isoforms differ in their heparin and heparan sulfate binding capacities as well as in their receptor affinities (9 ) , but their exact biological roles remain unclear. Most VEGF-producing cells appear to preferentially express VEGF 121 , VEGF 165 , and VEGF 189 (4 ) . VEGF 183 has a wide tissue distribution and may have not been detected earlier because of confusion with VEGF 189 (6 ) . VEGF 145 is one of the main variants produced by several cell lines derived from carcinomas of the female reproductive system (7 ) , and it has also been detected in ovarian and breast cancer tissue samples (10 ) . VEGF 148 was identified in human glomeruli (5 ), but there are no data concerning its expression in other tissues. VEGF 206 is a very rare isoform found in a human fetal liver library (8 ) .
We developed a real-time reverse transcription-PCR (RT-PCR) method for the quantification of 6 VEGF splice variants (VEGF 121 , VEGF 145 , VEGF 148 , VEGF 165 , VEGF 183 and VEGF 189 ) and applied it to 2 human breast cancer cell lines, MCF-7 and MDA-MB-231, and a human colorectal cancer cell line, COLO-205.
The sequences of the primers and probes used are presented in Table 1 , and the principle of the proposed assay is shown in Fig. 1〈 . A common forward primer (VEGFex3F) and a common pair of hybridization probes (VEGF-FL and VEGF-LC) were used (TIB MOLBIOL). The VEGFex3F primer and the VEGF-FL probe are located on exon 3, whereas the VEGF-LC probe spans the exon 3/4 boundaries to avoid genomic DNA detection. For the quantification of total VEGF mRNA, we used the VEGFex8R reverse primer located on exon 8 (common for all variants), which generated amplicons of various sizes ( 165 because VEGF 148 can also be amplified because the region exon 5/exon 7 is common in both variants.
Real-time PCR was performed in the LightCycler Instrument (Roche Applied Science) in a total volume of 10 L per glass capillary. For each reaction, 1 L of cDNA was placed in a 9-L reaction mixture containing 0.1 L of a temperature-released Taq DNA polymerase (5 U/L; Platinum DNA Polymerase; Invitrogen), 1 L of the supplied 10ϫ PCR buffer, 0.7 L of the supplied MgCl 2 (50 mM), 0.2 L of deoxynucleotide triphosphates (10 mM; Invitrogen), 0.15 L of bovine serum albumin [10 g/L; Sigma (11 )], 0.5 L of the primers and probes (3 M), and diethylpyrocarbonate-treated H 2 O. The cycling protocol was identical for all splice variants and total VEGF and consisted of an initial 5-min denaturation step at 95°C for activation of the DNA polymerase, followed by 50 cycles of denaturation at 95°C for 10 s, annealing at 60°C for 15 s, and extension at 72°C for 20 s.
For the development and analytical evaluation of the assay, we generated and used as calibrators PCR amplicons corresponding to the 6 VEGF splice variants studied. For this purpose, total RNA was extracted from MCF-7 cells; cDNA was synthesized and served as a template for the amplification of the targets of interest by real-time PCR. PCR products were separated on a 2% agarose gel. To establish a specific, sensitive, and reproducible realtime RT-PCR assay, we performed extensive optimization of primers, probes, and MgCl 2 concentrations as well as reaction temperatures and times. The analytical evaluation of the assay was performed with the prepared VEGF calibrators. For each splice variant, a calibration curve was generated from serial dilutions ranging from 10 6 to 10 copies/L of the target of interest. All calibration curves showed linearity over the entire quantification range with correlation coefficients Ͼ0.99. The between-day imprecision of the calibration curves ranged from 0.5% to 3.9% (Table 1 of the Data Supplement that accompanies the online version of this Technical Brief at http://www. clinchem.org/content/vol51/issue8/). The analytical detection limit of the method, defined as 3.3 times the SD of the crossing point for the less concentrated calibrator divided by the mean slope of the calibration curve, corresponded to 1 copy/L for each target, whereas the limit of quantification, defined as 3 times the detection limit, was 3 copies/L.
Because the amplicons generated by PCR have different sizes, the reaction efficiency could vary. However, the mean (SD) slopes of the 6 calibration curves ranged from Ϫ3.63 (0.29) to Ϫ3.95 (0.08), indicating comparable PCR efficiencies (1.79 -1.89), and the mean (SD) intercepts of the calibration curves ranged from 37.3 (0.9) to 38.3 (0.6) copies/L from day to day. When we used all of the data generated from the 6 different calibration curves to plot a single calibration curve, the correlation coefficient was 0.99, indicating that this grand mean calibration curve could be used for the quantification of all 6 splice variants as well as total VEGF. The assay was highly specific for each splice variant. When cDNA from 10 5 MCF-7 cells was used as a template for real-time PCR, agarose gel electrophoresis of the PCR products after 50 cycles revealed only one specific product of the desired length for each splice variant (Fig. 1B) .
We investigated the expression of VEGF splice variants in 3 cancer cell lines (MCF-7, MDA-MB-231, and COLO-205). VEGF 121 and VEGF 165 were the major variants expressed, followed by VEGF 189 , whereas VEGF 145 , VEGF 148 , and VEGF 183 were present only in small amounts (Fig. 1C) . VEGF 148 was detected for the first time in cancer cell lines.
In conclusion, we have developed a sensitive, specific real-time RT-PCR assay for the quantification of VEGF splice variants and total VEGF. A similar approach has already been described, but only the major VEGF variants VEGF 121 , VEGF 165 , and VEGF 189 were investigated (11 ) . In addition to these splice variants, we also included in our work the less-studied variants VEGF 145 , VEGF 148 , and VEGF 183 . The analytical performance of the assay was validated through a series of experiments based on VEGF calibrators, which were specifically designed, synthesized, and quantified in a novel way in our laboratory (13 ) . The use of PCR amplicon-based calibrators to generate calibration curves has also been described by others (14 ) . This approach is an alternative to the use of plasmid vectors and is useful for laboratories that do not have the facilities for transformation of bacterial cultures and subsequent plasmid DNA isolation.
The biological significance of the alternative splicing of the VEGF gene is still uncertain. We believe that the developed real-time RT-PCR assay, which provides rapid, accurate quantification of the expression of 6 VEGF variants, can be a promising tool for the elucidation of their role in promoting physiologic and pathologic angiogenesis. Our method can be applied to various samples for the separate quantification of a single VEGF splice variant of interest or of all 6 variants together and could serve as a model for the development of real-time RT-PCR assays for the quantification of other alternatively spliced genes.
